Center of Smart Laboratory and Molecular Medicine, School of Medicine, Chongqing University, Chongqing 400044, P. R. China.
Key Laboratory for Biorheological Science and Technology of Ministry of Education, State and Local Joint Engineering Laboratory for Vascular Implants, College of Bioengineering, Chongqing University, Chongqing 400044, P. R. China.
Anal Chem. 2022 Sep 27;94(38):13019-13027. doi: 10.1021/acs.analchem.2c01683. Epub 2022 Aug 18.
Cancer-derived small extracellular vesicles (csEVs) play critical roles in the genesis and development of various cancers. However, accurate detection of low-abundance csEVs remains particularly challenging due to the complex clinical sample composition. In the present study, we constructed a rogrammable sothermal ascade een nzyme-free eporter (PICKER) for the reliable detection and acquisition of the relative abundance of csEVs in total sEVs (tsEVs) by integrating dual-aptamer recognition (cancer-specific protein EpCAM and tetraspanin protein CD63) with a catalytic hairpin assembly (CHA) amplification. By employing this strategy, we were able to achieve a detection limit of 420 particles/μL csEVs. Particularly, we proposed a novel particle ratio index of csEV against tsEV (PR) to greatly eliminate errors from inconsistent centrifugation, which was calculated from the fluorescence ratio produced by csEVs and tsEVs. The PICKER showed a 1/10,000 discrimination capability by successfully picking out 1.0 × 10 csEV from 1.0 × 10 tsEV per microliter. We also found that the PR value increased proportional to the stages of breast cancer by analyzing EVs from clinical patients' plasma. Taken together, we established a PICKER strategy capable of accurately discriminating csEVs, and the proposed PR had been proven a potential indicator of breast cancer staging, paving the way toward facilitating cancer diagnosis and precision therapeutics.
肿瘤来源的小细胞外囊泡(csEVs)在各种癌症的发生和发展中起着关键作用。然而,由于临床样本组成复杂,低丰度 csEVs 的准确检测仍然极具挑战性。在本研究中,我们构建了一种可编程等温级联无酶报告基因(PICKER),通过将双适体识别(肿瘤特异性蛋白 EpCAM 和四跨膜蛋白 CD63)与催化发夹组装(CHA)扩增相结合,用于可靠检测和获取总外泌体(tsEVs)中 csEVs 的相对丰度。通过采用这种策略,我们能够实现 420 个/μL csEVs 的检测极限。特别地,我们提出了一种新的 csEV 相对于 tsEV 的粒子比指数(PR),以极大地消除由于离心不一致而产生的误差,该指数是由 csEVs 和 tsEVs 产生的荧光比值计算得出的。通过成功地从 1.0 × 10 tsEV 中挑选出 1.0 × 10 csEV,PICKER 表现出 1/10000 的区分能力。我们还发现,通过分析来自临床患者血浆的 EVs,PR 值随乳腺癌分期的增加而呈比例增加。总之,我们建立了一种能够准确区分 csEVs 的 PICKER 策略,所提出的 PR 已被证明是乳腺癌分期的潜在指标,为癌症诊断和精准治疗铺平了道路。